These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
Certified Fluka® pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to pharmacopeia primary standards
This product was designed, produced and verified for accuracy and stability in accordance with ISO/IEC 17025:2005 (AClass Cert AT-1467), ISO GUIDE 34:2009 (AClass Cert AR-1470).
Fluibiprofen is a cyclooxygenase (COX) inhibitor, which is an enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This decreases the prostaglandins which cause inflammation, pain, swelling and fever. Flurbiprofen inhibits the activity of both COX-1 and -2. The S enantiomer inhibits prostaglandin synthesis and has both anti-inflammatory and analgesic activity, while the Renantiomer does not inhibit prostaglandin synthesis and displays only analgesic activity.
FLUKA is a registered trademark of FLUKA GmbH